Report of Foreign Issuer (6-k)
08 Septembre 2020 - 12:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month September 2020
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name
into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes
¨ No x
Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes
¨ No x
Indicate by check mark whether
the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
Item
|
|
|
Sequential Page Number
|
1.
|
Other
Relevant Event, dated September 8, 2020
|
|
3
|
Grifols,
S.A.Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona - ESPAÑATel. [34] 935 710 500 Fax [34]
935 710 267 www.grifols.comPursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved
by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the followingOTHER RELEVANT
INFORMATIONGrifols informs that, it has executed an agreement with the remaining shareholders in Alkahest Inc. ("Alkahest") to
acquire the remaining shares of Alkahest (approximately 55%) in exchange of a total price of $146 million, on a debt free basis.
No additional financing will be required. The closing of the transaction is subject to the approval by the relevant antitrust
authorities, and is expected to take place in early 2021. Grifols already acquired a stake of approximately 45% of Alkahest in
March 2015. With this transaction, Grifols gains total control of Alkahest.Alkahest is a clinical stage biopharmaceutical company
targeting neurodegenerative and age- related diseases with transformative therapies derived from a deep understanding of the plasma
proteome in aging and disease.The transaction is part of Grifols' commitment with the research and development of therapeutic
alternatives designed to contribute to both scientific and social development. In addition, it is aligned with Grifols' strategy
of complementing its range of existing plasma protein therapies and diagnostic products to treat and diagnose serious diseases
and to extend the quality of human life.In Barcelona, on 7 September 2020Nuria Martín Barnés Secretary to the Board
of Directors
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A.
|
|
|
|
|
|
|
|
By:
|
/s/
David I. Bell
|
|
|
Name:
|
David
I. Bell
|
|
|
Title:
|
Authorized
Signatory
|
Date: September 8, 2020
Grifols (PK) (USOTC:GIKLY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Grifols (PK) (USOTC:GIKLY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024